Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biden vs. Pharma: ‘You Come For The King…’

Executive Summary

The president’s state of the union address comes after a year of mostly disappointing efforts for the administration on COVID and drug pricing.

You may also be interested in...



End Of An Era As Generic Versions Of BMS’s Controversial Blockbuster Revlimid Arrive

Revlimid was the driving force behind Celgene’s growth, but also became symbolic in the ongoing row over US drug prices.

Did The US FDA Mix Politics And Science With Its Cancer Guidance Announcement?

Three new guidances were announced the morning of President Biden’s State of the Union address, but experts said the move did not equate with past White House pressure on agency decisions.

Democratic Drug Pricing Push: Starting And Ending With Insulin?

When the Democratic party regained control of the US House of Representatives in 2019, their push to enact comprehensive drug pricing legislation began with a hearing on insulin. After four years, it might be ending with insulin as the sole focus after all.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS145784

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel